A PHASE I, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND FOOD EFFECT OF SINGLE AND MULTIPLE ORAL DOSES OF AZD7986 IN HEALTHY VOLUNTEERS
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2016
At a glance
- Drugs INS 1007 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 11 Aug 2016 Status changed from active, no longer recruiting to completed.
- 04 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 04 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016.